Back to top
more

10x Genomics (TXG)

(Real Time Quote from BATS)

$17.29 USD

17.29
888,855

-0.20 (-1.14%)

Updated Jul 15, 2024 02:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical Info Systems

Better trading starts here.

Zacks News

PacBio's (PACB) Latest Offering to Enhance Disease Discoveries

PacBio's (PACB) latest sequencing kit is expected to help generate insights into how single-cell research can power new disease discoveries and the identification of therapeutic targets across many categories.

Inspire (INSP) Stock Jumps 5.6%: Will It Continue to Soar?

Inspire (INSP) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of -42.50% and 0.10%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

American Well Corporation (AMWL) Reports Q2 Loss, Tops Revenue Estimates

American Well Corporation (AMWL) delivered earnings and revenue surprises of 0% and 3.56%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Azenta (AZTA) to Report a Decline in Earnings: What to Look Out for

Brooks (AZTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate 10x Genomics (TXG) to Report a Decline in Earnings: What to Look Out for

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Indrajit Bandyopadhyay headshot

3 Gene Sequencing Stocks With Potential to Gain in 2H22

Here we look at three stocks, PKI, TMO and TXG, with robust genome sequencing capabilities that investors can keep a watch on.

10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of -2.70% and 1.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

10x Genomics (TXG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Illumina (ILMN) Invests in Seven Additional Genomics Startups

Illumina's (ILMN) investment in seven new genomics companies is intended to advance breakthrough therapeutics, diagnostics, DNA storage, mental wellness and sustainable foods applications.

10x Genomics (TXG) Reports Q4 Loss, Lags Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of -166.67% and 2.83%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Will 10x Genomics (TXG) Report Negative Earnings Next Week? What You Should Know

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Trina Mukherjee headshot

3 Promising Gene Sequencing Stocks to Watch Out For in 2022

Here we look at three stocks, PKI, TMO and TXG, with robust genome sequencing capabilities that investors can keep a watch on.

10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of 16.67% and 0.99%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Wall Street Analysts See a 27% Upside in 10x Genomics (TXG): Can the Stock Really Move This High?

The mean of analysts' price targets for 10x Genomics (TXG) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Industry Outlook Highlights: 10x Genomics, Omnicell, Inspire Medical Systems and Cerner

Zacks Industry Outlook Highlights: 10x Genomics, Omnicell, Inspire Medical Systems and Cerner

Urmimala Biswas headshot

Buy 3 Medical Info Systems Stocks to Brave Industry-wide Challenges

Stocks like 10x Genomics Inc. (TXG), Omnicell, Inc. (OMCL) and Inspire Medical Systems, Inc. (INSP) are expected to gain despite pandemic-led disruptions.

Here's Why 10x Genomics (TXG) is Poised for a Turnaround After Losing 22.3% in 4 Weeks

10x Genomics (TXG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of 61.54% and 2.25%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Trina Mukherjee headshot

Medical Products' Aug 4 Earnings Roster: MCK, ABC & More

The Medical Product companies' second-quarter results are likely to reflect robust earnings and revenue growth on solid base business recovery.

Will 10x Genomics (TXG) Report Negative Earnings Next Week? What You Should Know

10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Daniel Laboe headshot

High-Growth Stocks Jump Back Into Investors' Favor

The short-term bottom for next-generation enterprises is in, and high multiple stocks are returning to investors' favor.

Strength Seen in 10x Genomics (TXG): Can Its 3.9% Jump Turn into More Strength?

10x Genomics (TXG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates

10x Genomics (TXG) delivered earnings and revenue surprises of 56.00% and 2.99%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?